Deadline (Application): Pfizer Quality Improvement RFP
Applicants should submit proposals bringing solutions for the expansion of HRRm testing in Canadian prostate cancer patients. Ideally, these will be projects with short-term impact, aimed at closing areas of large gaps. This may include, but not limited to:
- The development of solutions reducing inequities in access to HRRm tests in currently underserved regions or populations
- The development of solutions for early HRRm testing in patients with metastatic Castration-Sensitive Prostate Cancer (mCSPC)
- The development of solutions addressing important areas of inefficiencies or issues related to HRRm testing (any stages from test request to report results)
- The development of solutions to measure the evolution and performance of HRRm testing in Canadian real-world practice against current guidelines
Funding Range:
- Individual projects requesting up to a maximum of CAD $100,000 will be considered.
- The total available budget related to this RFP is CAD $200,000.
Internal Deadline: April 18, 2024 at 4:30pm. Contact email is ird@dal.ca.
Funder Deadline: May 2, 2024. Contact is Lori.Carpenter@pfizer.com, with the subject line 鈥淐losing the HRRm Testing Gap in Prostate Cancer Patients 20 February 2024鈥�
Time